文献速递临床试验与 GCP新药、器械与细胞基因治疗研发

一项多中心、随机、对照临床试验:研究床旁模型引导精准给药万古霉素对危重患儿的影响——BENEFICIAL试验

A multicentric, randomized, controlled clinical trial to study the impact of bedside model-informed precision dosing of vancomycin in critically ill children-BENEFICIAL trial.
PubMed 文献 · Trials · 2024-10-10

BENEFICIAL试验为多中心随机对照试验,纳入7家医院14个新生儿重症监护、儿科重症监护及儿科血液肿瘤病房单元的危重患儿,随机分配至模型引导精准给药(MIPD)组或标准治疗对照组。干预组采用MIPD计算器进行基于AUC的给药并早期额外采血监测,目标AUC24h为400-600(假设MIC为1 mg/L),主要终点为开始万古霉素治疗后24至48小时达到目标AUC24h/MIC 400-600的患者比例。

要点

  • 干预组采用MIPD计算器基于AUC给药,并在治疗最初数小时额外采血行治疗药物监测。
  • 目标AUC24h为400-600,假设病原菌MIC为1 mg/L。
  • 主要终点为开始万古霉素治疗后24至48小时达到目标AUC24h/MIC 400-600的患者比例。

核心结论

  • 该试验将阐明MIPD给药所宣称的获益,并为危重患儿万古霉素治疗的最优监测方式提供新见解。

研究设计与样本

  • 多中心、随机、对照临床试验,来自7家医院14个新生儿重症监护、儿科重症监护及儿科血液肿瘤病房单元的参与者被随机分配至干预组或标准治疗对照组。

主要发现

  • 干预组使用MIPD给药计算器进行基于AUC的给药,并结合治疗最初数小时额外采血行治疗药物监测;对照组按机构指南接受标准治疗给药与监测。
  • 目标AUC24h为400-600,假设MIC为1 mg/L。
  • 主要终点为开始万古霉素治疗后24至48小时达到目标AUC24h/MIC 400-600的患者比例。
  • 次要终点包括万古霉素治疗期间发生(加重)急性肾损伤的患者比例、开始治疗后48至72小时达到目标AUC24h/MIC 400-600的患者比例、临床治愈时间、病房单元住院时长、住院时长及30天全因死亡率。

关键数值与推荐

  • 目标AUC24h为400-600,假设MIC为1 mg/L。
  • 主要终点目标AUC24h/MIC为400-600,评价时间窗为开始万古霉素治疗后24至48小时。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Vancomycin is a commonly prescribed antibiotic to treat serious Gram-positive infections in children. The efficacy of vancomycin is known to be directly related to the pharmacokinetic/pharmacodynamic (PK/PD) index of the area under the concentration-time curve (AUC) divided by the minimal inhibitory concentration (MIC) of the pathogen. In most countries, steady-state plasma concentrations are used as a surrogate parameter for this target AUC/MIC, but this practice has some drawbacks. Hence, AUC-based dosing using model-informed precision dosing (MIPD) tools has been proposed for increasing the target attainment rate and reducing vancomycin-related nephrotoxicity. Solid scientific evidence for these claimed benefits is lacking in children. This randomized controlled trial aims to investigate the large-scale utility of MIPD dosing of vancomycin in critically ill children. METHODS: Participants from 14 neonatal intensive care, pediatric intensive care, and pediatric hemo-oncology ward units from 7 hospitals are randomly allocated to the intervention or standard-of-care comparator group. In the intervention group, a MIPD dosing calculator is used for AUC-based dosing, in combination with extra sampling for therapeutic drug monitoring in the first hours of treatment, as compared to standard-of-care. An AUC24h between 400 and 600 is targeted, assuming an MIC of 1 mg/L. Patients in the comparator group receive standard-of-care dosing and monitoring according to institutional guidelines. The primary endpoint is the proportion of patients reaching the target AUC24h/MIC of 400-600 between 24 and 48 h after the start of vancomycin treatment. Secondary endpoints are the proportion of patients with (worsening) acute kidney injury during vancomycin treatment, the proportion of patients reaching target AUC24h/MIC of 400-600 between 48 and 72 h after the start of vancomycin treatment, time to clinical cure, ward unit length-of-stay, hospital length-of-stay, and 30-day all-cause mortality. DISCUSSION: This trial will clarify the propagated benefits and provide new insights into how to optimally monitor vancomycin treatment in critically ill children. TRIAL REGISTRATION: Eudract number: 2019-004538-40. Registered on 2020-09-08 ClinicalTrials.gov NCT046666948. Registered on 2020-11-28.

来源:Trials,查看原文。版权归原作者所有。

引用

  1. De Cock PA, Colman R, Amza A, et al. A multicentric, randomized, controlled clinical trial to study the impact of bedside model-informed precision dosing of vancomycin in critically ill children-BENEFICIAL trial. Trials. 2024. PMID: 39390583. doi:10.1186/s13063-024-08512-z

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。